PDCD1 and cancer: Antibodies that target PD-L1 act mainly by inhibiting the binding of PD-L1 to PD-1, thus freeing cancer-specific CTLs to mediate killing of cancer cells that express PD-L1 (Pardoll, 2012; Mellman & Nelson, 2008).